Anti-CD100 Antibodies Neutralize Plexin-B1 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective CD100 neutralizing molecules for managing inflammatory and demyelinating diseases, as well as cancer associated with CD100 expression, as existing therapies do not adequately address the role of CD100 in these conditions.
Innovation Solution
Development of humanized monoclonal antibodies, such as MAb 2503, which specifically bind to CD100, neutralizing its activity and blocking its interaction with Plexin-B1, thereby inhibiting CD100-mediated processes in autoimmune diseases, inflammatory conditions, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used, then treatment of inflammatory and demyelinating diseases is provided, but the therapies do not adequately address the role of CD100 in these conditions
Solution Approach 1:
The patent introduces anti-CD100 antibodies as intermediary molecules that specifically bind to and neutralize CD100, thereby interrupting the pathological signaling pathways. These antibodies serve as mediators between the therapeutic need and the molecular target, providing a mechanism that existing therapies lack.
2Reliability
If CD100 neutralizing molecules are developed, then effective treatment for inflammatory and demyelinating diseases is achieved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts and isolates the specific molecular target (CD100) from the complex disease pathology, and develops targeted antibodies against this single molecule. This extraction approach simplifies the therapeutic strategy by focusing on one key pathological element rather than addressing the entire disease complexity.
3Object-affected harmful factors
If anti-CD100 antibodies are used, then CD100-mediated processes are inhibited, but the interaction with Plexin-B1 receptor is blocked
Solution Approach 1:
The patent converts the harmful effect of CD100-Plexin-B1 interaction (which drives inflammation and demyelination) into a beneficial therapeutic outcome. By blocking this interaction, the antibody transforms a pathological signaling pathway into a therapeutic mechanism that reduces disease severity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively reduce the severity of experimental allergic encephalomyelitis, collagen-induced arthritis, and cancer in mouse models by inhibiting CD100 activity, providing a therapeutic approach for conditions associated with CD100 expression.
Implementation Method 1
humanized MAb 2503, which specifically binds to human CD100, neutralizing its activity and blocking its interaction with the human Plexin-B1 receptor
Data Source
AI summary
Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.